Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03097614 · ClinicalTrials.gov registry record · NA
Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
A NA study, sponsored by Oculeve.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT03097614: Completed NA study, sponsored by Oculeve.
NCT03097614 is a NA study that has completed, run by Oculeve. The registered enrollment target is 57 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03097614, a NA study, has completed, sponsored by Oculeve.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
This study characterizes acute dry eye symptom control, assessed during exposure to a Controlled Adverse Environment, following use of the TrueTear for 45 days.
Primary Outcome
Eye Dryness Score using a visual analog scale assessed in the Controlled Adverse Environment (CAE). The participant rates their current eye dryness (both eyes simultaneously) by scoring 0 to indicate "no discomfort" and 100 to indicate "maximal discomfort". The assessment line length of the scale will be 100 mm.
Interventions
- DEVICE TrueTear
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-03-31 |
| Est. Completion | 2017-06-26 |
| Phase | NA |
What the finished NCT03097614 record still lists
NCT03097614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which TrueTear is the first listed.
NCT03097614 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03097614 about?
NCT03097614 is a clinical study titled "Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment". This study characterizes acute dry eye symptom control, assessed during exposure to a Controlled Adverse Environment, following use of the TrueTear for 45 days.
What is the current status of trial NCT03097614?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2017-03-31. Estimated completion is 2017-06-26.
What interventions are being tested in trial NCT03097614?
The interventions under investigation include: TrueTear (DEVICE).
Who is sponsoring clinical trial NCT03097614?
This trial is sponsored by Oculeve, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03097614's enrollment target sits among peer trials
57 1261st of 2000 higher than 739 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI